This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carling, T. Articles by Rastad, J. Search for Related Content PubMed PubMed Citation Articles by Carling, T. Articles by Rastad, J. Pubmed/NCBI databases OMIM Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL

Familial Hypercalcemia and Hypercalciuria Caused by a Novel Mutation in the Cytoplasmic Tail of the Calcium Receptor¹

Endocrine Surgery Unit, Department of Surgery (T.C., E.S., G.W., P.H., J.R.), Department of Genetics and Pathology (P.G., N.D.), and Department of Clinical Chemistry (P.R.), Uppsala University Hospital, S-751 85 Uppsala, Sweden; and Endocrine-Hypertension Division (M.B., S.T., E.M.B.), Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts 02115

Address correspondence and requests for reprints to: Tobias Carling, M.D., Ph.D., Endocrine Surgery Unit, Department of Surgery, Uppsala University Hospital, S-751 85 Uppsala, Sweden. E-mail: Tobias.Carling{at}kirurgi.uu.se

Familial hyperparathyroidism (HPT), characterized by hypercalcemia and hypercalciuria, and familial benign hypocalciuric hypercalcemia (FHH) are the most common causes of hereditary hypercalcemia. The calcium-sensing receptor (CaR) regulates PTH secretion and renal calcium excretion. Heterozygous inactivating mutations of the gene cause FHH, whereas CaR gene mutations have not been demonstrated in HPT. In a kindred with 20 affected individuals, the hypercalcemic disorder segregated with inappropriately higher serum PTH and magnesium levels and urinary calcium levels than in unaffected members. Subtotal parathyroidectomy revealed parathyroid gland hyperplasia/adenoma and corrected the biochemical signs of the disorder in seven of nine individuals. Linkage analysis mapped the condition to markers flanking the CaR gene on chromosome 3q. Sequence analysis revealed a mutation changing phenylalanine to leucine at codon 881 of the CaR gene, representing the first identified point mutation located within the cytoplasmic tail of the CaR. A construct of the mutant receptor (F881L) was expressed in human embryonic kidney cells (HEK 293), and demonstrated a right-shifted dose-response relationship between the extracellular and intracellular calcium concentrations. The hypercalcemic disorder of the present family is caused by an inactivating point mutation in the cytoplasmic tail of the CaR and displays clinical characteristics atypical of FHH and primary HPT.

This article has been cited by other articles:

				A. Scillitani, V. Guarnieri, C. Battista, S. De Geronimo, L. A. Muscarella, I. Chiodini, M. Cignarelli, S. Minisola, F. Bertoldo, C. M. Francucci, et al. Primary Hyperparathyroidism and the Presence of Kidney Stones Are Associated with Different Haplotypes of the Calcium-Sensing Receptor J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 277 - 283. [Abstract] [Full Text] [PDF]

				S. J. Marx and W. F. Simonds Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes Endocr. Rev., August 1, 2005; 26(5): 615 - 661. [Abstract] [Full Text] [PDF]

				S. Pidasheva, L. Canaff, W. F. Simonds, S. J. Marx, and G. N. Hendy Impaired cotranslational processing of the calcium-sensing receptor due to signal peptide missense mutations in familial hypocalciuric hypercalcemia Hum. Mol. Genet., June 15, 2005; 14(12): 1679 - 1690. [Abstract] [Full Text] [PDF]

				L. Forsberg, E. Bjorck, J. Hashemi, J. Zedenius, A. Hoog, L.-O. Farnebo, M. Reimers, and C. Larsson Distinction in gene expression profiles demonstrated in parathyroid adenomas by high-density oligoarray technology Eur. J. Endocrinol., March 1, 2005; 152(3): 459 - 470. [Abstract] [Full Text] [PDF]

				A. Wystrychowski, S. Pidasheva, L. Canaff, J. Chudek, F. Kokot, A. Wiecek, and G. N. Hendy Functional Characterization of Calcium-Sensing Receptor Codon 227 Mutations Presenting as Either Familial (Benign) Hypocalciuric Hypercalcemia or Neonatal Hyperparathyroidism J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 864 - 870. [Abstract] [Full Text] [PDF]

				E. M. Brown Mutant Extracellular Calcium-Sensing Receptors and Severity of Disease J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1246 - 1248. [Full Text] [PDF]

				C. A. Carrasco, A. A. Gonzalez, C. A. Carvajal, C. Campusano, E. Oestreicher, E. Arteaga, N. Wohllk, and C. E. Fardella Novel Intronic Mutation of MEN1 Gene Causing Familial Isolated Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 4124 - 4129. [Abstract] [Full Text] [PDF]

				J Warner, M Epstein, A Sweet, D Singh, J Burgess, S Stranks, P Hill, D Perry-Keene, D Learoyd, B Robinson, et al. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications J. Med. Genet., March 1, 2004; 41(3): 155 - 160. [Abstract] [Full Text] [PDF]

				A Villablanca, A Calender, L Forsberg, A Hoog, J-D Cheng, D Petillo, C Bauters, K Kahnoski, T Ebeling, P Salmela, et al. Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP) J. Med. Genet., March 1, 2004; 41(3): e32 - 32. [Full Text] [PDF]

				W. F. Simonds, C. M. Robbins, S. K. Agarwal, G. N. Hendy, J. D. Carpten, and S. J. Marx Familial Isolated Hyperparathyroidism Is Rarely Caused by Germline Mutation in HRPT2, the Gene for the Hyperparathyroidism-Jaw Tumor Syndrome J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 96 - 102. [Abstract] [Full Text] [PDF]

				L. Canaff and G. N. Hendy Human Calcium-sensing Receptor Gene. VITAMIN D RESPONSE ELEMENTS IN PROMOTERS P1 AND P2 CONFER TRANSCRIPTIONAL RESPONSIVENESS TO 1,25-DIHYDROXYVITAMIN D J. Biol. Chem., August 9, 2002; 277(33): 30337 - 30350. [Abstract] [Full Text] [PDF]

				E. Szabo, T. Carling, O. Hessman, and J. Rastad Loss of Heterozygosity in Parathyroid Glands of Familial Hypercalcemia with Hypercalciuria and Point Mutation in Calcium Receptor J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3961 - 3965. [Abstract] [Full Text] [PDF]

				K. Burski, B. Torjussen, A. Q. Paulsen, H. Boman, and J. Bollerslev Parathyroid Adenoma in a Subject with Familial Hypocalciuric Hypercalcemia: Coincidence or Causality? J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1015 - 1016. [Abstract] [Full Text] [PDF]

				M. L. Brandi, R. F. Gagel, A. Angeli, J. P. Bilezikian, P. Beck-Peccoz, C. Bordi, B. Conte-Devolx, A. Falchetti, R. G. Gheri, A. Libroia, et al. CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5658 - 5671. [Abstract] [Full Text] [PDF]

				W. Chang, S. Pratt, T.-H. Chen, L. Bourguignon, and D. Shoback Amino Acids in the Cytoplasmic C Terminus of the Parathyroid Ca2+-sensing Receptor Mediate Efficient Cell-surface Expression and Phospholipase C Activation J. Biol. Chem., November 16, 2001; 276(47): 44129 - 44136. [Abstract] [Full Text] [PDF]

				S. J. Marx Hyperparathyroid and Hypoparathyroid Disorders N. Engl. J. Med., December 21, 2000; 343(25): 1863 - 1875. [Full Text] [PDF]